Education
About Us
Working with TipRanks
Follow Us
Curevac N.V. (DE:5CV)
NASDAQ:5CV
5CV Stock Chart & Stats
€4.57
-€0.05(-1.16%)
At close: 4:00 PM EST
€4.57
-€0.05(-1.16%)
Day’s Range― - ―
52-Week Range€2.00 - €4.90
Previous CloseN/A
Volume42.95K
Average Volume (3M)299.09K
Market Cap
€822.36M
Enterprise Value€680.78M
Total Cash (Recent Filing)€395.81M
Total Debt (Recent Filing)€36.03M
Price to Earnings (P/E)6.2
Beta0.48
Next Earnings
Apr 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding225,181,640
10 Day Avg. Volume680,780
30 Day Avg. Volume299,086
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.06
Price to Sales (P/S)1.38
P/FCF Ratio8.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AcquisitionBNTX announced an all-stock acquisition offer for CVAC for ~$1.25B, with CVAC shares exchanged for $5.46 in BNTX ADS – a ~55% premium to CVAC’s trailing 3-month average price.
Financial PositionCVAC ended the period with €392.7mm in cash and equivalents, expected to fund operations into 2028.
Bears Say
Market UncertaintyThere is uncertainty in the respiratory vaccine franchise, partnered with GSK, as the COVID market wanes.
Operating LossOperating loss of €61.7mm was above consensus expectations.
CureVac News
5CV FAQ
What was Curevac N.V.’s price range in the past 12 months?
Curevac N.V. lowest stock price was €2.00 and its highest was €4.90 in the past 12 months.
What is Curevac N.V.’s market cap?
Curevac N.V.’s market cap is €822.36M.
When is Curevac N.V.’s upcoming earnings report date?
Curevac N.V.’s upcoming earnings report date is Apr 29, 2026 which is in 121 days.
How were Curevac N.V.’s earnings last quarter?
Curevac N.V. released its earnings results on Nov 24, 2025. The company reported -€0.07 earnings per share for the quarter, the consensus estimate of -€0.07 by €0.
Is Curevac N.V. overvalued?
According to Wall Street analysts Curevac N.V.’s price is currently Overvalued.
Does Curevac N.V. pay dividends?
Curevac N.V. does not currently pay dividends.
What is Curevac N.V.’s EPS estimate?
Curevac N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Curevac N.V. have?
Curevac N.V. has 225,181,640 shares outstanding.
What happened to Curevac N.V.’s price movement after its last earnings report?
Curevac N.V. reported an EPS of -€0.07 in its last earnings report, expectations of -€0.07. Following the earnings report the stock price went down -0.405%.
Which hedge fund is a major shareholder of Curevac N.V.?
Currently, no hedge funds are holding shares in DE:5CV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CureVac Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.98%
12-Months-Change
Fundamentals
Return on Equity
17.68%
Trailing 12-Months
Asset Growth
40.34%
Trailing 12-Months
Company Description
Curevac N.V.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Technical Analysis
Syndax Pharmaceuticals
―
Stoke Therapeutics
―
Enliven Therapeutics
―
AbCellera Biologics
―
LENZ Therapeutics
―
Options Prices
Currently, No data available
---